Ask AI

TROP2-Directed ADCs for Unmet Needs in HR+/HER2- MBC and TNBC

Text Module
Text Module Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: November 16, 2026

Expiration: May 15, 2027

See Activity Collection

Explore unmet needs after endocrine-based therapy in HR-positive/HER2-negative metastatic breast cancer and across treatment lines in metastatic TNBC and examine how TROP2-directed ADCs may address limitations of conventional chemotherapy.

TROP2 ADCs in Metastatic Breast Cancer

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with metastatic breast cancer (MBC) do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A patient with hormone receptor (HR)–positive/HER2-negative MBC has progressive disease after endocrine-based therapy and has experienced progressively shorter disease control with sequential single-agent chemotherapy.

Which of the following most accurately describes patients who are candidates for treatment with a TROP2-directed antibody–drug conjugate (ADC) based on currently FDA and European Medicines Agency approvals?

How confident are you in your answer?